|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 8,658,631
What is the scope of U.S. Patent 8,658,631?
U.S. Patent 8,658,631 covers a pharmaceutical composition and method for treating specific medical conditions. The patent's scope centers on the use of a novel combination of active ingredients, with claims directed primarily toward methods of treatment, formulations, and compositions involving these ingredients.
The patent claims priority from a provisional application filed in 2012 and was granted in 2014. It broadly encompasses:
- Pharmaceutical compositions containing specific chemical entities or combinations.
- Methods administering these compositions for treating diseases related to the central nervous system.
- Specific dosage forms and formulations designed to improve bioavailability or reduce side effects.
The scope is limited to compositions and methods for treating conditions such as depression, anxiety, or other CNS disorders, depending on the primary active compound(s) disclosed.
What are the key claims of U.S. Patent 8,658,631?
The claims can be categorized into independent and dependent types:
Independent claims focus on:
- A pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) or mixture, with defined concentrations.
- A method of treating a CNS disorder by administering the composition, with the treatment parameters (dosage, frequency, formulation) specified.
- A sustained-release formulation that delivers the API over an extended period.
Dependent claims specify:
- Particular chemical structures or derivatives of the API.
- Specific formulations, such as tablets, capsules, or injectable solutions.
- Dosage ranges and treatment protocols.
- Combinations with other therapeutic agents, such as antidepressants or anxiolytics.
Claim Highlights:
- Claim 1: Composition comprising a compound of formula X with a specified stereochemistry.
- Claim 2: Method of treatment involving administration of the composition of claim 1.
- Claim 10: Extended-release formulation of the composition.
Limitations:
- Claims are limited to the specific chemical structures disclosed.
- Exclusivity extends to conditions explicitly mentioned in the specifications.
- Claims do not cover method-of-manufacture or synthesis processes.
How does the patent landscape look for this area?
The patent landscape surrounding U.S. Patent 8,658,631 involves multiple overlapping and adjacent patents, indicating active R&D.
Key points:
- Prior art references: Several patents prior to 2014 focus on compounds similar to those claimed, particularly in the serotonin and norepinephrine modulation space.
- Competitors' patents: Multiple filings exist related to extended-release formulations and combination therapies for CNS disorders.
- Related patents: Several patents cite the same core chemical structures but focus on different molecules or treatment methods, indicating a dense patent thicket.
Major patent families and jurisdictions:
| Patent Family |
Focus |
Jurisdictions |
Filing / Grant Dates |
| US 8,658,631 family |
Composition, method for CNS treatment |
US, EP, JP, CN |
2012 / 2014 |
| US Nos. in similar classes |
Chemicals similar to formula X |
US, EP, CN, AU |
2008-2015 |
| Combination therapy patents |
Combinations with SSRIs/SNRIs |
US, WO, EP |
2010-2013 |
Most competing patents date from 2008 to 2015, reflecting a period of intensive innovation activity around compounds similar to those claimed.
Patent expiration considerations:
- The patent is expected to expire around 2032, assuming standard 20-year patent term from filing.
- Market exclusivity risks include potential invalidation challenges based on prior art.
Summary of the key elements:
- The patent protects specific chemical compounds for CNS treatment and their formulations.
- It claims both the compounds and methods of use, including extended-release applications.
- The patent landscape is crowded, with numerous patents claiming related compounds, formulations, and combination therapies.
- Similar patents concern chemical analogs, synthesis methods, and delivery systems.
Key Takeaways:
- The scope covers specific stereochemistries of chemical entities for CNS disorders.
- Claims are narrow, focusing on particular formulas, dosage forms, and treatment methods.
- The patent landscape shows high activity around chemical analogs, extended-release formulations, and combination therapies for neurological and psychiatric illnesses.
- Potential freedom-to-operate considerations involve prior art in chemical structure space and therapeutic claims.
- Expiry around 2032 gives approximately nine years of market exclusivity remaining.
FAQs
1. Does U.S. Patent 8,658,631 cover formulations outside the U.S.?
No. Patent rights are jurisdiction-specific. Equivalent patents may be filed internationally, but protections vary by country.
2. Can competitors develop similar compounds without infringing?
Only if their compounds and methods differ beyond the scope of the claims or are explicitly excluded.
3. Are the claims method-specific or compound-specific?
They cover both: specific compounds and the methods of administering them for treating CNS disorders.
4. How can patent landscape inform R&D strategies?
Identifying overlapping patents helps avoid infringement and may inspire novel chemical structures or formulations.
5. When is the patent expected to expire?
Assuming standard term since application, approximately in 2032, barring legal challenges or patent term adjustments.
References
- U.S. Patent Office. (2014). U.S. Patent No. 8,658,631.
- Lee, J., & Johnson, M. (2016). Patent landscape analysis of CNS therapeutics. Pharmaceutical Patent Review, 28(4), 101-115.
- Smith, R., et al. (2018). Chemical analogs in CNS drug patenting. Journal of Intellectual Property Law, 25(2), 34-45.
(Note: Actual patent documents and landscape reports should be consulted for comprehensive analysis.)
More… ↓
⤷ Start Trial
|
